Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...
CD2 through its interaction with the cell surface protein, CD58, has critical functions for the activation of T cells and ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...
Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...
T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...
Medeze Group Public Company Limited (Medeze Group), Thailand's foremost hematopoietic (HSC), mesenchymal stem cell (MSC) bank ...
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback